ENTA
Q4 2026 EPS Estimate
$-0.63
Nov 16, 2026
Revenue Estimate
$16M

Analyst Sentiment

Wall St. Consensus
Buy
16 analysts·Moderate coverage
69
Score
14 Buy (88%)0 Hold (0%)2 Sell (12%)
Rating Breakdown
Strong Buy
00%
Buy
1488%
Hold
00%
Sell
213%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$20.00
+52.3%
Consensus
$20.00
+52.3%
Bull
$20.00
+52.3%
12-Month Target Range16 analysts
$20.00$20.00$20.00
Current $13.13Consensus
Current Price
$13.13
Upside to Consensus
$6.87

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-0.55%
EPS
FY2028
Rev+7.69%
EPS
FY2029
Rev+40.87%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$64M$64M$69M$97M$153M
Low$61M$63M$35M$80M$126M
High$67M$64M$117M$116M$183M
EBITDA Avg$-64M$-64M$-69M$-97M$-153M
Low$-67M$-64M$-117M$-116M$-183M
High$-61M$-63M$-35M$-80M$-126M
EBIT Avg$-64M$-64M$-69M$-97M$-153M
Low$-67M$-64M$-117M$-116M$-183M
High$-61M$-63M$-35M$-80M$-126M
Net Income Avg$-62M$-58M$-67M$-44M$-33M
Low$-71M$-68M$-84M$-56M$-41M
High$-40M$-33M$-27M$-34M$-26M
EPS Avg$-2.60$-2.37$-2.27$-2.07$-1.54
Low$-3.34$-3.17$-3.92$-2.61$-1.94
High$-1.87$-1.56$-1.27$-1.61$-1.20
Analysts (Rev / EPS)2 / 24 / 43 / 31 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027
Revenue Avg$16M$16M$15M$15M$15M
Low$15M$15M$14M$14M$14M
High$17M$17M$16M$16M$16M
EBITDA Avg$-16M$-16M$-15M$-15M$-15M
Low$-17M$-17M$-16M$-16M$-16M
High$-15M$-15M$-14M$-14M$-14M
EBIT Avg$-16M$-16M$-15M$-15M$-15M
Low$-17M$-17M$-16M$-16M$-16M
High$-15M$-15M$-14M$-14M$-14M
Net Income Avg$-20M$-12M$-14M$-14M$-15M
Low$-30M$-13M$-15M$-16M$-17M
High$-10M$-11M$-13M$-13M$-14M
EPS Avg$-0.69$-0.41$-0.47$-0.49$-0.53
Low$-1.04$-0.44$-0.51$-0.54$-0.58
High$-0.33$-0.38$-0.43$-0.46$-0.49
Analysts (Rev / EPS)2 / 21 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Jun 23, 2026H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
Target:$20.00
+49.6%from $13.37
Oct 1, 2025Jefferies
Enanta upgraded to Buy from Hold at Jefferies
Target:$20.00
+83.7%from $10.88
Jun 3, 2025JMP Securities
Enanta price target raised to $24 from $23 at Citizens JMP
Target:$24.00
+233.8%from $7.19
Dec 9, 2022H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56
Target:$56.00
+33.5%from $41.96
Nov 22, 2022RBC Capital
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54
Target:$54.00
+16.4%from $46.40
Jul 29, 2022Piper Sandler
Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler
Target:$87.00
+69.7%from $51.27
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.